Business Context and Reporting Period
This Form 8-K Current Report was filed by ArTara Therapeutics, Inc. (also referred to as Protara Therapeutics, Inc. in the request metadata) on February 11, 2020, reporting events occurring on February 6, 2020. The company is a life sciences entity focused on rare diseases, with its common stock trading on the Nasdaq Capital Market under the symbol TARA.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on executive personnel changes and the terms of their employment agreements.
Material Changes
- Appointment of Chief Financial Officer: Blaine Davis was appointed as Chief Financial Officer, effective February 11, 2020. He serves as the principal financial and accounting officer, replacing Jesse Shefferman (President and CEO) who had temporarily held these roles.
- Executive Employment Agreement (Blaine Davis):
- Annual Base Salary: $385,000.
- Annual Discretionary Bonus: 40% of base salary.
- Equity Grant: Stock option for 94,000 shares with a four-year vesting schedule (25% after one year, monthly thereafter).
- Severance: Upon termination without cause or resignation for good reason, Davis is entitled to 12 months of base salary, 12 months of target bonus, and 12 months of healthcare reimbursement.
- Change in Control: Acceleration of 100% of unvested equity awards if terminated within 12 months of a change in control.
- Executive Employment Agreement (Julio Casoy, M.D.):
- Role: Chief Medical Officer.
- Effective Date: February 13, 2020 (salary effective January 10, 2020).
- Annual Base Salary: $400,000.
- Annual Discretionary Bonus: 35% of base salary.
- Severance: Upon termination without cause or resignation for good reason, Dr. Casoy is entitled to 9 months of base salary, 9 months of target bonus, and 12 months of healthcare reimbursement.
- Change in Control: Acceleration of 100% of unvested equity awards if terminated within 18 months of a change in control.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of general business risks. The primary contingency noted is the requirement for executives to execute a general release to receive severance benefits. The full text of the employment agreements is expected to be filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2019.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price for Blaine Davis's 94,000 stock options in the full 10-K filing.
- Confirm the total number of shares reserved under the Proteon Therapeutics, Inc. Amended and Restated 2014 Equity Incentive Plan to assess dilution impact.
- Review the upcoming 10-K filing for the complete text of the Executive Employment Agreements for both Mr. Davis and Dr. Casoy.
- Monitor the company's cash position to ensure it can support the new executive compensation structure, given the lack of revenue data in this report.